Railcar products and services provider Trinity (NYSE:TRN) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 39.8% year on year to $506.2 million. Its GAAP profit of $0.17 per share was 37% below analysts’ consensus estimates.
Today's focus centres on corporate earnings, critical economic data releases, central bank decisions on interest rates, and developments in trade negotiations ahead of the new U.S. tariffs set to take effect this Friday.
Electronic equipment provider Vontier (NYSE:VNT) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.1% year on year to $773.5 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $750 million was less impressive, coming in 0.7% below expectations. Its GAAP profit of $0.62 per share was 1.9% above analysts’ consensus estimates.
Eaton Corp. (ETN) is a top dividend stock with strong profitability, financial health, and consistent dividend growth, making it ideal for long-term investors.
Engineered components manufacturer for critical industries ITT Inc. (NYSE: ITT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $972.4 million. Its non-GAAP profit of $1.64 per share was 1.8% above analysts’ consensus estimates.
A major U.S. Army contract and strong analyst ratings underpin the bull case for Red Cat stock, whose recent price dip presents a compelling opportunity.
Diversified healthcare company CVS Health (NYSE:CVS) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 8.4% year on year to $98.92 billion. Its non-GAAP profit of $1.81 per share was 23.9% above analysts’ consensus estimates.
Discover how Dorman Products (DORM) aligns with Peter Lynch's GARP strategy—steady growth, fair valuation, strong financials, and a solid market position in automotive aftermarket parts.
August could be a particularly strong month for the S&P 500, driven by earnings season and the growth outlook; this examines five buys investors should consider
While the Fed voted to maintain the Fed Funds rate at 4.25-4.50%, Michelle Bowman and Christopher Wallace cast dissenting votes in favor of reducing rates.
Healthcare tech company Omnicell (NASDAQ:OMCL) announced better-than-expected revenue in Q2 CY2025, with sales up 5% year on year to $290.6 million. On top of that, next quarter’s revenue guidance ($295 million at the midpoint) was surprisingly good and 3.2% above what analysts were expecting. Its non-GAAP profit of $0.45 per share was 66.7% above analysts’ consensus estimates.
Document technology company Xerox (NASDAQ:XRX) beat Wall Street’s revenue expectations in Q2 CY2025, but sales were flat year on year at $1.58 billion. Its non-GAAP profit of $3 per share was significantly above analysts’ consensus estimates.
The Caviar Cruise strategy identifies high-quality stocks like Champion Homes (SKY), excelling in EBIT growth, ROIC, and low debt, ideal for long-term investors.
The US Federal Reserve held rates steady as expected, but effectively dashed expectations of a rate cut at its September meeting, sending the US Dollar soaring.
Cruise company Norwegian Cruise Line (NYSE:NCLH) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 6.1% year on year to $2.52 billion. Its non-GAAP profit of $0.51 per share was in line with analysts’ consensus estimates.
ASML Holding NV (NASDAQ:ASML) combines strong fundamentals—high profitability, steady growth—with a potential technical turnaround, making it a compelling high-growth stock in semiconductor tech.
Medical technology company Teleflex (NYSE:TFX) announced better-than-expected revenue in Q2 CY2025, with sales up 2.3% year on year to $780.9 million. Its non-GAAP profit of $3.73 per share was 10.8% above analysts’ consensus estimates.
Copper prices plunged 20% after Trump excluded refined copper from a 50% import tariff, ending a rally. Other factors and upcoming Chilean election may affect future prices.
Health insurance company Cigna (NYSE:CI) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 11.1% year on year to $67.18 billion. Its non-GAAP profit of $7.20 per share was 0.6% above analysts’ consensus estimates.
Government and sustainable technology solutions company KBR (NYSE:KBR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 5.2% year on year to $1.95 billion. The company’s full-year revenue guidance of $8 billion at the midpoint came in 7.3% below analysts’ estimates. Its non-GAAP profit of $0.91 per share was 3% above analysts’ consensus estimates.
Medical device company Integra LifeSciences (NASDAQ:IART) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $415.6 million. The company expects next quarter’s revenue to be around $415 million, close to analysts’ estimates. Its non-GAAP profit of $0.45 per share was 4.4% above analysts’ consensus estimates.
Manufacturing services provider Proto Labs (NYSE:PRLB) announced better-than-expected revenue in Q2 CY2025, with sales up 7.5% year on year to $135.1 million. On top of that, next quarter’s revenue guidance ($134 million at the midpoint) was surprisingly good and 3.1% above what analysts were expecting. Its non-GAAP profit of $0.41 per share was 19.9% above analysts’ consensus estimates.
Brian Armstrong, CEO of Coinbase, recalled an old encounter with Ethereum (CRYPTO: ETH) co-founder Vitalik Buterin and the inefficiencies of the U.S. immigration system that contributed to the blockchain’s creation.
